Y
ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Haematology · Lancet Haematol · 2026-11-01

In 130 adults with KMT2A-rearranged leukaemia undergoing allogeneic HSCT in China, adding decitabine to busulfan-cyclophosphamide conditioning lowered 2-year relapse (12% vs 29%; HR 0·41, p=0·017), with similar grade 3–5 adverse events.

RCTn = 130
Hu et al. Decitabine plus busulfan-cyclophosphamide versus busulfan-cyclophosphamide myeloablative conditioning before allogeneic haematopoietic stem cell transplantation for reducing risk of relapse in adult KMT2A‑rearranged leukaemia in China: an open-label, multicentre, randomised phase 3 trial
Haematology · Lancet Haematol · 2026-09-17

Open-label period of the phase 3 LUNA3 trial in adults with previously treated immune thrombocytopenia: 46 of 198 (23%) given rilzabrutinib had stable platelet responses; 26% had treatment-related adverse events, most often grade 1–2 diarrhoea and nausea; 1% serious.

Open-label extensionn = 180
Kuter et al. Clinical activity and safety of rilzabrutinib in patients with previously treated immune thrombocytopenia (LUNA3): results from the open-label period of a phase 3 trial
Haematology · Lancet Haematol · 2026-09-01

In 73 adults (66 analysed) with newly diagnosed double-hit lymphoma, adding venetoclax to DA-EPOCH-R did not improve progression-free survival (median 7·7 vs 28·4 months; HR 1·13, p=0·75). On-treatment deaths 17% vs 3% led to early closure; 24-month overall survival 52% vs 72%.

RCTn = 73
Abramson et al. Venetoclax added to dose-adjusted EPOCH-R for newly diagnosed double-hit lymphomas: phase 2 results from ALLIANCE A051701, an open-label, randomised, controlled, phase 2-3 trial

Sign in to react

Enter your email and we send a one-time link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.